BELLUS Health is developing camlipixant (BLU-5937), an investigational P2X3 antagonist, for the treatment of refractory chronic cough. Preclinical and clinical evidence have linked the P2X3 receptor and refractory chronic cough to a sensory nerve dysfunction that can lead to cough hypersensitivity. Camlipixant has the potential to address the significant unmet need for an efficacious, safe and well tolerated treatment for refractory chronic cough.
We have initiated the CALM Phase 3 clinical program (CALM-1 and CALM-2) in refractory chronic cough, with each trial evaluating the efficacy, safety and tolerability of camlipixant. CALM-1 and CALM-2 are running concurrently, and each will recruit approximately 675 adult participants with refractory chronic cough.
Camlipixant (BLU-5937) remains in development and has not been approved for commercialization. The clinical safety and effectiveness of camlipixant have not yet been fully established. The development of this product, and an investment in BELLUS Health common shares, involves a significant amount of risks. We invite you to review our Annual Information Form to learn more about these risk factors. A summary of these can also be reviewed here.